Habs H, Habs M
Cancer Lett. 1981 Jun;13(1):63-9. doi: 10.1016/0304-3835(81)90087-2.
Pretreatment with disulfiram (DSF, 1000 mg/kg p.o.) 2 h prior to intraperitoneal injection of 1-(2-hydroxyethyl)3-(2-chloroethyl)-3-nitrosourea (HECNU, NSC 29485) reduced the acute toxicity of HECNU by 50% in Sprague--Dawley rats. Thereafter the effect of this additional treatment on the chemotherapeutic activity of HECNU was investigated. After intraperitoneal transplantation of Yoshida sarcoma ascites cells untreated rats had a median survival time of 8 days. The therapeutic response to a single application of HECNU alone or of DSF followed by HECNU was compared. HECNU was injected intravenously at logarithmically increasing doses from 15 to 61.8 mg/kg. The maximum survival time was increased to about 14 days in rats treated with HECNU. Pretreatment with DSF (1000 mg/kg) resulted in identical or slightly higher life expectancies; it thus reduced the toxic side effects of HECNU without inhibiting its antitumor potency.
在腹腔注射1-(2-羟乙基)-3-(2-氯乙基)-3-亚硝基脲（HECNU，NSC 29485）前2小时，用双硫仑（DSF，1000毫克/千克，口服）对Sprague-Dawley大鼠进行预处理，可使HECNU的急性毒性降低50%。此后，研究了这种额外处理对HECNU化疗活性的影响。在腹腔移植吉田肉瘤腹水细胞后，未处理的大鼠中位生存时间为8天。比较了单独单次应用HECNU或DSF后再应用HECNU的治疗反应。以对数递增剂量从15毫克/千克至61.8毫克/千克静脉注射HECNU。用HECNU治疗的大鼠最大生存时间延长至约14天。用DSF（1000毫克/千克）预处理导致相同或略高的预期寿命；因此，它降低了HECNU的毒副作用，而不抑制其抗肿瘤效力。
